Clinical Trials/NCT04831450

NCT04831450WithdrawnPhase 2

Phase II Trial of Maintenance Cemiplimab-rwlc After Concurrent Chemoradiotherapy (CRT) in Intermediate and High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)

University of Miami0 sitesStarted: July 2022Last updated: August 4, 2022

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 2
Status: Withdrawn
Sponsor: University of Miami
Primary Endpoint: Progression-Free Survival (PFS)

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

The purpose of this study is to evaluate the experimental immunotherapy agent cemiplimab-rwlc when given after completion of chemotherapy and radiation treatment and determine if it will improve progression free survival and cure rates in patients with PD-L1 positive locally advanced head and neck cancer.

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Histological diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
•Intermediate or high-risk disease defined by the following:
•Squamous Cell Carcinoma of the oral cavity, larynx or hypopharynx American Joint Committee on Cancer (AJCC) 8th Stage III-IVB
•p16-Negative oropharynx SCC, AJCC 8th Stage III-IVB
•p16--positive oropharyngeal SCC, AJCC 8th stage II-III
•Tumor must have documented Programmed Death (PD) Ligand (L) -1 Combined Positive Score (CPS) PD-L1 CPS ≥ 1 by immunohistochemistry (IHC).
•Prior therapy for advanced stage HNSCC with definitive Standard of Care (SoC) CRT Intensity Modulated Radiation Therapy (IMRT (66-70 Gy) with concurrent Cisplatin with curative intent. Patients must have received a total cumulative dose of cisplatin of ≥ 200 mg/m2 or equivalent carboplatin plus taxanes combination per investigator criteria during concurrent treatment.
•No clinical or radiographic evidence of progressive disease at the time of enrollment.
•Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤
•Adequate bone marrow function, including:
•Absolute Neutrophil Count (ANC) ≥ 1,000/µL or ≥ 1.0 x 10^9/L.
•Platelets ≥ 75,000/µL or ≥ 100 x 10^9/L.
•Hemoglobin ≥ 8 g/dL (may have been transfused).
•Adequate renal function, as determined by an estimated creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft- Gault.
•Adequate liver function, including:
•Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
•Aspartate and alanine aminotransferase (AST and ALT) < 2.5 x ULN.
•Pregnancy test (for patients of childbearing potential) negative at screening.
•Male patients able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use two methods of contraception (at least one of which is considered to be highly effective throughout the study and for at least 3 months after the last dose of cemiplimab-rwlc.
•Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative, as allowed by local guideline/practice) has been informed of all pertinent aspects of the study.

Exclusion Criteria

•Prior immunotherapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T lymphocyte Associated (CTLA)-4 antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.
•Major surgery ≤ 4 weeks prior to enrollment.
•Prior malignancy (other than the current Head and Neck cancer or in situ disease) requiring tumor-directed therapy within the last 2 years prior to enrollment, or concurrent malignancy associated with clinical instability. Exceptions for disease within the 2 years are superficial esophageal cancer (TIS or T1a) fully resected by endoscopy, prostate cancer (Gleason score ≤6) either curatively treated or deemed to not require treatment, ductal in situ carcinoma of the breast that has completed curative treatment, adequately treated basal cell or squamous cell skin cancer.
•Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
•Active infection requiring systemic therapy.
•Use of immunosuppressive medication at time of enrollment, except the following:
•Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or equivalent
•Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
•Prior organ transplantation including allogenic stem-cell transplantation.
•Diagnosis of prior immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
•Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA [ribonucleic acid] if anti-HCV antibody screening test positive).
•Pregnant female patients, breastfeeding female patients, and male patients able to father children and female patients of childbearing potential who are unwilling or unable to use 2 methods of contraception (at least one of which is considered to be highly effective) for at least 3 months after the last dose of cemiplimab-rwlc.
•Patients with impaired decision-making capacity.

Arms & Interventions

Cemiplimab After CRT in HNSCC

Experimental

Participants will receive Cemiplimab for 6 consecutive months (a total of 8 cycles) 14-42 days after completion of standard of care CRT.

Intervention: Cemiplimab-Rwlc (Drug)

Outcomes

Primary Outcomes

Progression-Free Survival (PFS)

Time Frame: Up to 2 years

Progression-Free Survival (PFS) is defined as the elapsed time from the date of starting maintenance treatment until disease progression or death (whichever occurs first). Patients who have not had an event will be censored at the date of last disease assessment documenting the patient was free of progression. Progression will be assessed using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.

Secondary Outcomes

Incidence of Treatment-Related Toxicity and Adverse Events(Up to 9 months)
PFS Rate(Up to 1 year)
Overall Survival (OS)(Up to 2 years)

Investigators

Sponsor

University of Miami

Sponsor Class

Other

Responsible Party

Principal Investigator

Chukwuemeka Ikpeazu

Associate Professor of Clinical

University of Miami

Similar Trials

Recruiting

Phase 1

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell CarcinomaMerkel Cell Carcinoma

NCT04975152H. Lee Moffitt Cancer Center and Research Institute36

Active, not recruiting

Phase 2

NCT04862650Marcelo Bonomi46

Terminated

Phase 2

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCCCutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma of the Head and Neck

NCT04242173H. Lee Moffitt Cancer Center and Research Institute3

Withdrawn

Phase 2

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)Cutaneous Squamous Cell Carcinoma

NCT06384820Regeneron Pharmaceuticals

Completed

Phase 2

Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic CyclophosphamideMetastatic Breast Cancer

NCT03139851Centre Leon Berard36